Survival prolongation by rationale innovative genomics (SPRING): An international WIN consortium phase I study exploring safety and efficacy of avelumab, palbociclib, and axitinib in advanced non-small cell lung cancer (NSCLC) with integrated genomic and transcriptomic correlates. Solomon, B, Callejo, A, Bar, J, Berchem, G, Bazhenova, L, Saintigny, P, Raymond, E, Girard, N, Sulaiman, R, Bresson, C, & others Annals of Oncology, 30:v648, Elsevier, 2019.
bibtex   
@article{solomon2019survival,
  title={Survival prolongation by rationale innovative genomics (SPRING): An international WIN consortium phase I study exploring safety and efficacy of avelumab, palbociclib, and axitinib in advanced non-small cell lung cancer (NSCLC) with integrated genomic and transcriptomic correlates},
  author={Solomon, B and Callejo, A and Bar, J and Berchem, G and Bazhenova, L and Saintigny, P and Raymond, E and Girard, N and Sulaiman, R and Bresson, C and others},
  journal={Annals of Oncology},
  volume={30},
  pages={v648},
  year={2019},
  publisher={Elsevier}
}

Downloads: 0